Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HH2710 in Advanced Tumors
NCT04198818Phase 2Terminated
- Sponsor
- Haihe
- Start
- Jan 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of HH2710 in solid tumor (advanced stage), melanoma, non-small cell lung cancer (NSCLC) and 2 more, sponsored by Haihe. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicities and 1 more. Started Jan 2020; status: terminated.
02
Drugs
HH2710
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung cancer (NSCLC)Erdheim-Chester disease (ECD)Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT04198818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198818.